These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28521846)

  • 1. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.
    Thase ME; Gommoll C; Chen C; Kramer K; Khan A; Durgam S
    CNS Spectr; 2017 Dec; 22(6):475-483. PubMed ID: 28521846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
    Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
    CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials.
    Thase ME; Edwards J; Durgam S; Chen C; Chang CT; Mathews M; Gommoll CP
    Int Clin Psychopharmacol; 2017 Sep; 32(5):281-288. PubMed ID: 28538024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
    McIntyre RS; Gommoll C; Chen C; Ruth A
    CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
    Blum SI; Tourkodimitris S; Ruth A
    J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
    Acharya N; Rosen AS; Polzer JP; D'Souza DN; Perahia DG; Cavazzoni PA; Baldessarini RJ
    J Clin Psychopharmacol; 2006 Dec; 26(6):587-94. PubMed ID: 17110815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study.
    Durgam S; Chen C; Migliore R; Prakash C; Thase ME
    Depress Anxiety; 2019 Mar; 36(3):225-234. PubMed ID: 30675739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
    Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
    J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
    Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
    J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.
    Kornstein SG; Gommoll C; Chen C; Kramer K
    J Affect Disord; 2016 Mar; 193():137-43. PubMed ID: 26773906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
    Emslie GJ; Wells TG; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2015 May; 25(4):293-305. PubMed ID: 25978741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
    Shelton RC; Fava M; Freeman MP; Thase ME; Papakostas GI; Jha MK; Trivedi MH; Dirks B; Liu K; Stankovic S
    J Affect Disord; 2020 Dec; 277():478-485. PubMed ID: 32871535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode.
    Seemüller F; Riedel M; Obermeier M; Bauer M; Adli M; Mundt C; Holsboer F; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Jäger M; Henkel V; Möller HJ
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):181-9. PubMed ID: 18662490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
    Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.
    Zhou Y; Lan X; Wang C; Zhang F; Liu H; Fu L; Li W; Ye Y; Hu Z; Chao Z; Ning Y
    J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):507-518. PubMed ID: 37414272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.